Review on the progress of laboratory tests for activity judgment of pulmonary tuberculosis

doi:10.3969/j.issn.1000-6621.2020.06.016

Abstract

Abstract:

The epidemic situation of pulmonary tuberculosis in China is challenging. The pathogenic test of Mycobacterium tuberculosis is the “golden indicator” for the diagnosis of pulmonary tuberculosis, but the diagnosis becomes difficult when the test results are negative. This review introduces the current evaluation methods of laboratory tests for activity judgment of pulmonary tuberculosis, such as Mycobacterium tuberculosis antigens, inflammatory and acute-phase reaction markers, immunological indicators, and blood transcription markers; points out the problems of current laboratory tests for activity judgment and clinical implementation; and discusses its future development.

Key words: Tuberculosis, pulmonary, Activity judgment, Laboratory techniques and methods, Review literature as topic

FU Liang, DENG Guo-fang. Review on the progress of laboratory tests for activity judgment of pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(6): 626-629. doi: 10.3969/j.issn.1000-6621.2020.06.016

References 38

[1]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
[2]	张慧, 刘剑君 . 建国70年来结核病防治工作要览与展望. 中国防痨杂志, 2019,41(9):913-916.
[3]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09.
[4]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 中国防痨杂志编辑委员会. 肺结核活动性判断规范及临床应用专家共识. 中国防痨杂志, 2020,42(4):301-307.
[5]	To KW, Kam KM, Chan DPC , et al. Utility of GeneXpert in analysis of bronchoalveolar lavage samples from patients with suspected tuberculosis in an intermediate-burden setting. J Infect, 2018,77(4):296-301. doi: 10.1016/j.jinf.2018.06.011 URL
[6]	Rindi L, Alì G, Fabiani B , et al. Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by GeneXpert MTB/RIF. Tuberculosis (Edinb), 2017,106:53-55. doi: 10.1016/j.tube.2017.06.005 URL
[7]	宋婧, 车南颖 . 结核病分子病理学诊断技术临床应用进展. 中国防痨杂志, 2018,40(11):1221-1225.
[8]	Maclean E, Pai M . Urine lipoarabinomannan for tuberculosis diagnosis: evolution and prospects. Clin Chem, 2018,64(8):1133-1135. doi: 10.1373/clinchem.2018.286625 URL
[9]	Peter JG, Zijenah LS, Chanda D , et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet, 2016,387(10024):1187-1197. doi: 10.1016/S0140-6736(15)01092-2 URL
[10]	World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: Policy Guidance. Geneva: World Health Organization, 2015.
[11]	Website of the Global Tuberculosis Community Advisory Board. Webinar: LAM as a pharmacodynamic biomarker and drug development tool for TB(EB/OL). 2017-06-22.[2020-04-20]. http://www.tbonline.info/posts/2017/6/10/webinar-lam-pharmacodynamic-biomarker-and-drug-dev/.
[12]	Liu C, Zhao Z, Fan J , et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci U S A, 2017,114(15):3969-3974. doi: 10.1073/pnas.1621360114 URL
[13]	Santos VS, Goletti D, Kontogianni K , et al. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. Clin Microbiol Infect, 2019,25(2):169-177. doi: 10.1016/j.cmi.2018.07.017 URL
[14]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础学组和临床学组. 现阶段结核抗体检测在我国临床应用的专家共识. 中国防痨杂志, 2018,40(1):9-13.
[15]	Blauenfeldt T, Petrone L, Del NF , et al. Interplay of DDP4 and IP-10 as a potential mechanism for cell recruitment to tuberculosis lesions. Front Immunol, 2018,9:1456. doi: 10.3389/fimmu.2018.01456 URL
[16]	魏兰, 秦学博, 段小亮 , 等. 血γ干扰素诱导蛋白10检测对判断肺结核患者治疗效果的价值. 中国防痨杂志, 2019,41(2):181-185.
[17]	Miranda P, Gil-Santana L, Oliveira MG , et al. Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation. PLoS One, 2017,12(4):e175278.
[18]	Yoon C, Semitala FC, Atuhumuza E , et al. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infect Dis, 2017,17(12):1285-1292. doi: 10.1016/S1473-3099(17)30488-7 URL
[19]	Chegou NN, Sutherland JS, Malherbe S , et al. Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax, 2016,71(9):785-794. doi: 10.1136/thoraxjnl-2015-207999 URL
[20]	Bobosha K, Tjon KFE, van den Eeden S J , et al. Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae. PLoS Negl Trop Dis, 2014,8(5):e2845. doi: 10.1371/journal.pntd.0002845 URL
[21]	Goletti D, Lindestam Arlehamn CS, Scriba TJ , et al. Can we predict tuberculosis cure? What tools are available? Eur Respir J, 2018,52(5):1801089. doi: 10.1183/13993003.01089-2018 URL
[22]	Petruccioli E, Navarra A, Petrone L , et al. Use of several immunological markers to model the probability of activetuberculosis. Diagn Microbiol Infect Dis, 2016,86(2):169-171. doi: 10.1016/j.diagmicrobio.2016.06.007 URL
[23]	World Health Organization. Use of tuberculosis interferon-Gamma Release Assays (IGRAs) In low- and middle-income countries: Policy statement. Geneva: World Health Organization, 2011.
[24]	Goletti D, Butera O, Bizzoni F , et al. Region of difference 1 antigen-specific CD4⁺ memory T cells correlate with a favora-ble outcome of tuberculosis. J Infect Dis, 2006,194(7):984-992. doi: 10.1086/jid.2006.194.issue-7 URL
[25]	Petruccioli E, Vanini V, Chiacchio T , et al. Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb), 2017,106:38-43. doi: 10.1016/j.tube.2017.06.002 URL
[26]	Denkinger CM, Pai M, Patel M , et al. Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. J Clin Microbiol, 2013,51(2):607-610. doi: 10.1128/JCM.02278-12 URL
[27]	Carrara S, Vincenti D, Petrosillo N , et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis, 2004,38(5):754-756. doi: 10.1086/cid.2004.38.issue-5 URL
[28]	Aiken AM, Hill PC, Fox A , et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis, 2006,6:66. doi: 10.1186/1471-2334-6-66 URL
[29]	Pourakbari B, Mamishi S, Benvari S , et al. Can Interferon-γ Release Assays Be Useful for Monitoring the Response to Anti-Tuberculosis Treatment? A Systematic Review and Meta-analysis. Arch Immunol Ther Exp (Warsz), 2020,68(1):4. doi: 10.1007/s00005-020-00568-4 URL
[30]	Wang F, Yu J, Zhou Y , et al. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis. Front Immunol, 2018,9:1047. doi: 10.3389/fimmu.2018.01047 URL
[31]	Wang S, He L, Wu J , et al. Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis. Front Immunol, 2019,10:2948. doi: 10.3389/fimmu.2019.02948 URL
[32]	Cliff JM, Lee JS, Constantinou N , et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis, 2013,207(1):18-29. doi: 10.1093/infdis/jis499 URL
[33]	Bos LD, Sterk PJ, Schultz MJ . Volatile metabolites of pathogens: a systematic review. PLoS Pathog, 2013,9(5):e1003311. doi: 10.1371/journal.ppat.1003311 URL
[34]	Combrink M, Loots DT, du Preez I . Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. Toxicol Lett, 2020,322:104-110. doi: 10.1016/j.toxlet.2020.01.018 URL
[35]	Bruderer T, Gaisl T, Gaugg MT , et al. On-Line Analysis of Exhaled Breath Focus Review. Chem Rev, 2019,119(19):10803-10828. doi: 10.1021/acs.chemrev.9b00005 URL
[36]	Phillips M, Cataneo RN, Condos R , et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb), 2007,87(1):44-52. doi: 10.1016/j.tube.2006.03.004 URL
[37]	Phillips M, Basa-Dalay V, Bothamley G , et al. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb), 2010,90(2):145-151. doi: 10.1016/j.tube.2010.01.003 URL
[38]	Nakhleh MK, Jeries R, Gharra A , et al. Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. Eur Respir J, 2014,43(5):1522-1525. doi: 10.1183/09031936.00019114 URL